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Summary 
This report describes the production of a set of plasmid solutions, ERM®-AD623a, b, c, d, e, and f, 
certified for the copy number ratio of specific desoxyribonucleic acid (DNA) fragments per plasmid 
and for the copy number concentration of the plasmid. The material has been produced following 
ISO Guide 34:2009 [1]. 
DNA fragments specific for the transcript of breakpoint cluster region gene (BCR), the transcript of 
the glucuronidase beta gene (GUSB) and the fusion transcript from the BCR gene and the c-abl 
oncogene 1 (BCR-ABL b3a2) were cloned into a pUC18 vector to construct the pIRMM-0099 
plasmid. The sequence identity of the pIRMM-0099 plasmid was determined by dye terminator 
cycle sequencing of the entire plasmid. The plasmid was diluted to six different concentration 
levels.  
Between unit-heterogeneity has been quantified and stability during dispatch and storage have 
been assessed in accordance with ISO Guide 35:2006 [2]. The material was characterised by an 
intercomparison among laboratories of demonstrated competence and adhering to ISO/IEC 
17025:2005 [3]. Uncertainties of the certified values were calculated in compliance with the Guide 
to the Expression of Uncertainty in Measurement (GUM) [4] and include uncertainties related to 
possible heterogeneity and instability and to characterisation. 
The CRM has been accepted as European Reference Material (ERM®) after peer evaluation by 
the partners of the European Reference Material consortium. 
The certified values and their uncertainties are listed below: 
Number of specific DNA fragments per plasmid 
 
Certified value b) Uncertainty c) 
BCR-ABL b3a2 transcript a) 1 negligible 
BCR transcript a) 1 negligible 
GUSB transcript a) 1 negligible 
a) The sequence identity has been confirmed by dideoxy termination sequencing of the entire plasmid. The 
estimated error probability of the sequence identification of each fragment is lower than 0.0002 % 
b) The certified value is traceable to the International System of units (SI). 
c) The uncertainty of the certified value refers to a standard uncertainty. It is estimated by a type B evaluation 
based on information provided in Section 6 of the corresponding certification report.  
Copy number concentration of the plasmid d) 
 
Certified value e) [cp/µL] Uncertainty f) [cp/µL] 
ERM®-AD623a 1.08×106 0.13×106 
ERM®-AD623b 1.08×105 0.11×105 
ERM®-AD623c 1.03×104 0.10×104 
ERM®-AD623d 1.02×103 0.09×103 
ERM®-AD623e 1.04×102 0.10×102 
ERM®-AD623f 10.0 1.5 
d) The copy number concentration of the plasmid is defined by the PCR method amplifying two PCR 
targets specific for BCR-ABL b3a2 and ABL using primers and probes according to Gabert et al. 2003 and 
Beillard et al. 2003.  
e) Unweighted mean of independent measurements obtained in three different laboratories. The certified 
value and its uncertainty are traceable to the International System of units (SI). 
f) The certified uncertainty is the expanded uncertainty with a coverage factor k = 2 corresponding to a 
level of confidence of approximately 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the 
Expression of Uncertainty in Measurement (GUM:1995), ISO, 2009.  
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Disclaimer 
Certain commercial equipment, instruments, and materials are identified in this paper to specify 
adequately the experimental procedure. In no case does such identification imply 
recommendation or endorsement by the European Commission, nor does it imply that the material 
or equipment is necessarily the best available for the purpose.  
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Glossary 
6-FAM 6-carboxylfluorescein dye 
ABL C-ABL oncogene 1 
ANOVA  Analysis of variance 
bp Base pair 
BCR Breakpoint cluster region gene 
cDNA Complementary DNA 
CML Chronic myeloid leukaemia 
cp Copy number 
CRM Certified reference material 
d Correction factor 
DNA Deoxyribonucleic acid 
dPCR Digital Polymerase Chain Reaction 
E. coli Escherichia coli  
EDTA Ethylenediamine tetraacetic acid 
ERM® Trademark of European Reference Materials 
GUM Guide to the Expression of Uncertainty in Measurements  
[ISO/IEC Guide 98-3:2008] 
GUSB Glucuronidase beta gene 
IRMM Institute for Reference Materials and Measurements of the JRC  
ISO International Organization for Standardization  
JRC Joint Research Centre of the European Commission 
k Coverage factor 
LB Luria-Bertani 
MGB Dihydrocyclopyrroloindole tripeptide minor groove binder 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
MRD Minimal residual disease 
n Number of replicates per unit 
N Number of samples (units) analysed 
n.a. Not accepted 
n.c. Not calculated 
PCR Polymerase chain reaction 
qPCR Quantitative real time polymerase chain reaction 
rel Index denoting relative figures (uncertainties etc.) 
RNA Ribonucleic acid 
RSD Relative standard deviation 
r2 Coefficient of determination of the linear regression 
s Standard deviation 
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sbb Between-unit standard deviation; an additional index "rel" is added as 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
SI International System of Units 
smeas Standard deviation of measurement data; an additional index "rel" is added as 
appropriate 
SNP Single nucleotide polymorphism 
swithin Standard deviation within groups as obtained from ANOVA; an additional index 
"rel" is added as appropriate 
swb Within-unit standard deviation 
T1E0.01 Buffer contained 1 mmol/L TRIS and, 0.01 mmol/L EDTA at pH 8.0 
T Temperature 
t Time 
ti Time point for each replicate 
TAMRA Tetramethyl-6-Carboxyrhodamine 
TaqMan® Thermus aquaticus (Taq) DNA polymerase-based technology for fluorescent 
signal generation during real-time PCR 
tsl Proposed shelf life 
tRNA Transfer RNA 
TRIS Tris(hydroxymethyl)aminomethane 
u Standard uncertainty  
U Expanded uncertainty 
u*bb  Standard uncertainty related to a maximum between-unit heterogeneity that 
could be hidden by method repeatability; an additional index "rel" is added as 
appropriate 
ubb Standard uncertainty related to a possible between-unit heterogeneity;  an 
additional index "rel" is added as appropriate 
uchar  Standard uncertainty of the material characterisation; an additional index "rel" is 
added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is added as 
appropriate 
ud Uncertainty of the correction factor d; an additional index "rel" is added as 
appropriate 
ults Standard uncertainty of the long-term stability; an additional index "rel" is added 
as appropriate 
usts Standard uncertainty of the short-term stability 
X-gal 5-bromo-4-chloro-3-inodlyl-β-D-galactopyranoside 
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1 Introduction  
 
1.1 Background: need for the CRM  
Philadelphia translocation is a specific chromosomal abnormality caused by the exchange of two 
fragments from the human chromosomes 9 and 22, also described as t(9;22)(q34;q11). This 
translocation joins two otherwise separate genes: c-abl oncogene 1 (ABL) and breakpoint cluster 
region (BCR) gene together to the fusion gene BCR-ABL. Breakpoints can occur at different 
positions within the BCR and ABL gene. The two major transcripts are called b2a2 (joining exon 
13 of BCR with exon 2 of ABL) and b3a2 (joining exon 14 of BCR with exon 2 of ABL). 
The BCR-ABL gene plays a causal role in the pathogenesis of chronic myeloid leukaemia (CML) 
[7]. CML is characterised by massive increase of premature myeloid cells in the blood and has an 
incidence of 1 to 2 per 100000 persons [8]. Treatment of CML is focused on the inhibition of the 
BCR-ABL protein and usually leads to return of normal blood cell counts [9]. Few leukemic cells 
however persist in most patients, called minimal residual disease (MRD). Therefore, lifelong 
treatment is required and the risk of therapy resistance and disease relapse is present [10].  
Regularly monitoring of MRD can identify patients in need of therapeutic intervention before the 
onset of overt relapse. Levels of the BCR-ABL transcript have shown to be a good indicator for 
the amount for leukemic cells present in the blood of the patients [11]. The measurement 
procedure consists of several steps. White blood cells are isolated from a blood sample and 
messenger RNA (mRNA) is extracted. After transfer of the mRNA to complementary DNA (cDNA) 
by reverse transcription the amount of BCR-ABL b3a2 transcript is measured by quantitative real 
time PCR (qPCR). Together with the BCR-ABL transcript levels, the transcript of a control gene is 
also quantified to control for variations in reverse transcription (RT) PCR and the sample 
preparation. The results are expressed as a ratio of the number of copies of BCR-ABL b3a2 
transcript to the number of copies of the control gene transcript.  
Results obtained by qPCR are influenced by a larger number of factors including the composition 
of the mastermix and the instrument used [12]. The copy number ratio of BCR-ABL b3a2 
transcript to the control gene transcript in the patients' samples is determined using a calibration 
curve from standards with known copy number concentrations. In addition, the calibration curve is 
also used to estimate the absolute copy number concentration of the control gene in the patient 
samples. This value is important to assure the quality of the sample preparation steps before the 
qPCR including the reverse transcriptase step. Especially for patient samples in which the BCR-
ABL transcript is not detected the copy number concentration measured for the control gene 
transcript gives an indication about the sensitivity of the measurement. 
1.2 Choice of the material 
There are several requirements for a material to be used as a calibrant for the qPCR reactions, in 
addition to requirements for homogeneity, stability and metrological traceability. 
The calibrant is used to determine the ratio of the number of copies of BCR-ABL b3a2 transcript 
and the transcript of the control gene. The calibrant should have a certified value for this copy 
number ratio and the associated uncertainty should be as small as possible. Therefore it was 
decided to produce a plasmid that contains the sequences of both the BCR-ABL b3a2 transcript 
and the control gene transcript.  
A number of different qPCR methods have been developed and validated. These methods use 
different control genes and different primer and probe sets. The three following genes have been 
studied extensively and appear to be the most suitable control genes: the native form of ABL, the 
native form BCR and glucuronidase beta gene (GUSB) [13]. The sequence of the BCR-ABL b3a2 
transcript and the native form of ABL largely overlap and most primers and probes used to amplify 
the ABL transcript will also amplify the BCR-ABL b3a2 transcript. It is therefore not necessary to 
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add a specific DNA fragment from the native ABL transcript. The plasmid should contain DNA 
fragments specific for the transcripts from BCR-ABL, GUSB and BCR. These fragments should be 
large enough to allow the use of different primers and probes. 
The plasmid calibrant will also be used to estimate the number of copies of the control gene 
transcript present in the cDNA sample of the patient. The calibrant should therefore have a 
certified value for the copy number concentration of the plasmid.  
Ideally, the calibration curve for a qPCR reaction should contain at least six points and cover a 5-
log range [12]. The calibration curve should also comprise the concentration levels of both the 
BCR-ABL b3a2 transcript and the control gene transcript that are usually present in the patient 
samples. Therefore, it was decided to produce a set of plasmid dilutions with nominal copy 
number concentrations ranging from 106 cp/µL to 10 cp/µL. 
1.3 Design of the project 
DNA fragments specific for the transcript of BCR-ABL b3a2, BCR and GUSB were obtained by 
using cDNA from the K562 cell line [14] as a template. These DNA fragments were cloned into a 
pUC18 vector to construct the pIRMM-0099 plasmid. The different plasmid solutions of ERM-
AD623 were processed by diluting the pIRMM-0099 plasmid into a buffer containing 1 mmol/L 
Tris(hydroxymethyl)aminomethane (TRIS), 0.01 mmol/L Ethylenediamine tetraacetic acid (EDTA) 
pH 8.0 (called T1E0.01 buffer) and 50 ng/µL transfer RNA (tRNA) from Escherichia coli (E. coli) as 
background nucleic acids.  
Homogeneity and stability studies were performed with duplex qPCR amplifying the two PCR 
targets on the DNA fragment specific for the BCR-ABL b3a2 transcript. One PCR target is located 
at the BCR-ABL junction site (called BCR-ABL target) while the other is located in the DNA 
sequence originating from the ABL gene (called ABL target). The primers and probes and PCR 
conditions used, have been validated in an intercomparison study [5, 6]. The probe of the BCR-
ABL b3a2 target was 5’ labelled with 6-VIC and the quencher MGB was located at the 3’ side. For 
the probe of the ABL target the 5’ label was 6-FAM and TAMRA was used as a quencher at the 3’ 
side. The primers and probes and PCR conditions are described in Annex A.  
Within the homogeneity and stability studies each vial was measured three times (n = 3) and one 
measurement result is the mean result from three wells (triplicate). Measurements were performed 
on 96 well plates and the volume of the qPCR reaction was 25 µL per well. Five µL of DNA 
solution were added to 20 µL master mix containing the appropriate primers and probe for the 
duplex qPCR. TaqMan Universal PCR MasterMix (Applied Biosystems, Lennik, BE) was used 
and the qPCR reactions were performed on an ABI 7900. Data were analysed with the SDS 2.4 
using the automatic base line and threshold settings.  
On each qPCR plate a calibration curve was added containing 7 concentration points. This 
calibration curve was made from a plasmid solution of the pIRMM-0099 which was extracted 
independently and its copy number concentration was determined by digital PCR (dPCR).  
The number of specific DNA fragments per plasmid (the BCR-ABL b3a2 transcript fragment, the 
BCR transcript fragment and the GUSB transcript fragment) is defined by the DNA sequence of 
the plasmid. The DNA sequence of the pIRMM-0099 plasmid was determined by dideoxy 
terminator sequencing by two expert laboratories.  
The copy number concentration of the plasmid was determined by dPCR measurements 
performed in three laboratories. Digital PCR relies on single molecule detection since the PCR 
solution is distributed across a large number of individual partitions [15]. After amplification, the 
concentration of target DNA in the solution is estimated using a binominal approximation based on 
the number of partitions containing amplified product and the total number of partitions analysed.  
Digital PCR reactions were performed on the BioMark system (Fluidigm, South San Francisco, 
US) using the 12.765 Digital arrays (Fluidigm). This nanofluidic digital array comprises 765 
individual partitions of approximately 6 nL volume each with total volume per panel of 
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approximately 4.6 µL. The BCR-ABL b3a2 target and the ABL target were amplified using the 
same primers and probes and PCR conditions as for the qPCR (Annex A).  
Samples from ERM-AD623a, b, c and were gravimetrically diluted in serial dilution to reach a 
nominal copy number concentration of 500 cp/µL. Samples from ERM-AD623e and f were 
analysed undiluted. Afterwards the DNA sample was added to the reaction mix containing 
Taqman universal mix (Applied Biosystems), sample loading reagent (Fluidigm) and primers and 
probes and the DNA. This reaction mix was analysed on five panels of one digital array and the 
mean of these five panels was considered as one measurement result. The obtained raw data 
were analysed with the BioMark Digital PCR Analysis software.  
A limited commutability study was performed by nine expert laboratories using six different qPCR 
methods to determine the ratio of BCR-ABL b3a2 transcript to the control gene transcript. The 
participating laboratories received sets of the six plasmid solutions of ERM-AD623 and two 
dilutions of a cDNA sample mimicking real patient samples. From each set of plasmid solutions 
several calibration curves were measured. The two cDNA solutions were also measured and their 
copy number ratio of BCR-ABL b3a2/control gene was determined using the different calibration 
curves.  
 
2 Participants 
 
2.1 Project management and evaluation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
2.2 Processing  
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
Salisbury District Hospital, National Genetics Reference Laboratory (Wessex), Salisbury, UK 
2.3Homogeneity study and stability study 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO/IEC 17025 for testing and calibration laboratories, BELAC No. 268-TEST) 
2.4 Characterisation 
2.4.1 Sequence identity of the plasmid 
Baseclear BV, Leiden, NL  
Eurofins Madigenomix GmBH, Martinsried, DE 
2.4.2 Copy number concentration  
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO/IEC 17025 for testing and calibration laboratories, BELAC No. 268-TEST) 
 
LGC Limited, Molecular and Cell Biology Team, Teddington, UK 
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National Measurement Institute (NMI), Department of Innovation, Industry, Science and Research, 
Bioanalysis Group, West Lindfield, AU 
2.5 Commutability study 
Academy of Athens, Biomedical Research Foundation, Haematology Research Laboratory, 
Athens, GR 
Catholic University of Korea, Seoul, KR 
Erasme Hospital , Medical Genetics Department, Brussels, BE  
(accredited to ISO 15189 for medical laboratories, BELAC No 396-MED) 
IMVS Pathology, Division of molecular pathology, Adelaine, AU  
(accredited to ISO 17025 for testing and calibration laboratories, Nata No 2348) 
Salisbury District Hospital, National Genetics Reference Laboratory (Wessex), Salisbury, UK 
(accredited to CPA standards, CPA No 1175) 
Royal Perth Hospital, Path West Laboratory Medicine WA, Molecular Heamatology, Perth, AU 
(accredited to ISO 17025 for testing and calibration laboratories, Nata No 2390) 
University Hospital Bern, Haematology Department, Molecular Diagnostics, Bern, CH 
(accredited to ISO 17025 for testing and calibration laboratories, SAS STS 435) 
University of Frankfurt, Department of Haematology, MRD labor, Frankfurt, DE 
University medical centre Mannheim, Mannheim, DE 
 
 3 Material processing and process control 
 
3.1 Origin of the starting material  
3.1.1 Cloning of BCR and GUSB single target plasmids  
A 963 bp fragment of the BCR transcript was amplified by AmpliTaq Gold® DNA Polymerase 
(Applied Biosystems, Lennik, BE) using cDNA from the K562 cell line (Hammersmith Hospital, 
London, UK) as template. The amplicon was ligated in the plasmid vector pCR®2.1 (Invitrogen, 
Carlsbad, CA, US) and E. coli Top10 were transformed with the ligation products. Transformed 
cells carrying the plasmid with insert were selected on Luria-Bertani (LB) plates supplemented 
with ampicillin and 5-bromo-4-chloro-3-inodlyl-β-D-galactopyranoside (X-gal) to allow colour 
based selection of the colonies bearing a plasmid with insert. The sequence of the insert was 
checked by dideoxy terminator sequencing of plasmid DNA isolated from single colonies. One 
single clone bearing this plasmid (called intermediated plasmid pCR2.1_BCR) was selected. 
An 813 bp fragment of the GUSB transcript was amplified by AmpliTaq Gold® DNA polymerase 
using cDNA from the K562 cell line as template. The amplicon was ligated in the plasmid vector 
pCR2.1 (Invitrogen) and E. coli Top10 cells were transformed with the ligation products. 
Transformed cells carrying the plasmid with insert were selected on LB plates supplemented with 
ampicillin and X-gal. The sequence of the insert was checked by dideoxy terminator sequencing 
of plasmid DNA isolated from single colonies. One single clone bearing this plasmid (called 
intermediated plasmid pCR2.1_GUSB) was selected. 
3.1.2 Construction of the multiple target plasmid  
The multiple target plasmid was assembled in three consecutive DNA fragment insertions into the 
plasmid vector pUC18.  
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Intermediate plasmid pCR2.1_BCR was digested with EcoRI and the fragment containing the 
BCR insert was cloned into the pUC18 vector digested with EcoRI. The relevant digestion 
products were ligated and E. coli XL1 blue competent cells were transformed with the ligation 
products. Transformed cells were selected on ampicillin-containing LB plates. Correct insertions 
were identified by restriction enzyme digestion of plasmid DNA extracts from single bacterial 
colonies. The corresponding plasmid was named intermediate plasmid pUC18_BCR.  
The fragment of the GUSB transcript was inserted by restriction digestion of the intermediate 
plasmid pCR2.1_GUSB and pUC18_BCR using XbaI and KpnI. After ligation E. coli XL1 blue 
competent cells were transformed and plated on LB plates containing ampicillin. Correct insertions 
were identified by restriction enzyme digestion of plasmid DNA extracts from single bacterial 
colonies. The corresponding plasmid was named intermediate pUC18_BCR_GUSB. 
A 1397 bp fragment of the BCR-ABL b3a2 transcript was amplified by AmpliTaq Gold® DNA 
polymerase using cDNA extracted from the K562 cell line as template. The PCR primers used had 
additional SalI restriction sites at the 5’ end. The PCR amplicon was then digested with SalI and 
ligated into intermediate plasmid pUC18_BCR_GUSB that had been digested with SalI. After 
ligation E. coli XL1 blue competent cells were transformed and plated on LB plates containing 
ampicillin. Correct insertions were identified by restriction enzyme digestion and dideoxy 
terminator sequencing of plasmid DNA extracts from single bacterial colonies. The corresponding 
plasmid was named pIRMM-0099. One single clone bearing this final plasmid was plated again on 
a LB plate supplemented with ampicillin and from this plate one isolated colony was selected. 
After a second confirmation of the presence of the correct DNA sequence of the plasmid by 
restriction digest and sequencing of the inserts this clone was selected as the starting point for the 
processing of ERM-AD623a, b, c, d, e and f. Figure 1 shows the circular map of the plasmid.  
 
Figure 1: Circular map of the plasmid. The arrows represent the inserts from the transcripts fragments of 
BCR, GUSB and BCR-ABL b3a2. The rectangles show the location of the PCR targets BCR-ABL b3a2 and 
ABL used in this report to quantify the copy number concentration of the plasmid. The restriction site of 
EcoRV is also shown.   
3.2 Processing  
3.2.1 Preparation of stock solution of plasmid pIRMM-0099 
Two hundred mL of LB medium containing 100 µg/mL of ampicillin were inoculated with a single 
colony of E. coli containing plasmid pIRMM-0099 and shaken at 200 rpm overnight at 37 °C. The 
plasmid was extracted and purified using the QIAfilter Plasmid Maxi Kit (Qiagen Benelux B.V., 
Venlo, NL). The purified plasmid was dissolved in T1E0.01 buffer. The identity of the plasmid was 
BCR‐ABL 
target 
ABL target 
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checked by DNA restriction analysis and agarose gel electrophoresis as described in Section 
3.3.1.  
From this solution of the circular plasmid pIRMM-0099 two aliquots were set aside to be sent to 
two independent sequencing service companies to determine the complete nucleic acid sequence 
of the plasmid.  
The plasmid in the remaining solution was restricted with EcoRV-HFTM (New England Biolabs, 
Ipswich, MA, US). Complete restriction was checked by agarose gel electrophoresis. The 
linearised plasmid was purified using the Qiaquick® gel extraction kit (Qiagen) and eluted from the 
Qiaquick silica membrane with T1E0.01 buffer.  
The DNA mass concentration of the linearised plasmid solution was determined with fluorometry 
using the Picogreen dsDNA quantification kit (Molecular Probes Inc, Eugene, OR, US). 
Measurements were performed according to the manufacturer's instructions using a lambda DNA 
standard solution. The measured DNA mass concentration and standard deviation were 
210 ± 3 µg/mL (n = 6). The purity of the nucleic acid preparation was assessed 
spectrophotometrically by measuring the UV absorbance of the sample at 230 nm, 260 nm and 
280 nm. Additional information can be found in Section 3.3. 
Based on DNA mass concentration, the copy number concentration of the plasmid solution was 
estimated, applying the following equation.  
plasmid
ADNA
M
NCionconcentratnumbercopy      Equation 1 
CDNA DNA mass concentration 
AN  Avogadro constant  
plasmidM  molar mass of the pIRMM0099 plasmid  
Calculation of the molar mass of the pIRMM0099 plasmid was based on the DNA sequence of the 
plasmid and the molar mass of each nucleotide monohosphate [16].  
The estimated copy number concentration of the linearised plasmid solution with a DNA mass 
concentration of 210 ng/µL was 3.43 x 1010 cp/µL. 
The solution containing linear plasmid was diluted to 35 ng/µL (estimated copy number 
concentration: 5.71 x 109 cp/µL) in T1E0.01 buffer to prepare the stock solution for processing the 
individual CRMs. This stock solution was separated in 8 aliquots which were stored at -20 °C until 
further use. 
3.2.2 Preparation of individual CRMs 
Each CRM was processed separately starting from one individual aliquot of the stock solution. 
Dilutions were made in T1E0.01 buffer contained 50 ng/µL tRNA from E. coli (Sigma-Aldrich, 
Bornem, BE).  
Afterwards, the plasmid solution was sterilised by filtration through a polyethersulfone (PES) filter 
(Merck Millipore, Overijse, BE) and filled manually in pre-labelled high recovery polypropylene 
vials under sterile conditions. Each vial was filled with 600 µL of plasmid containing solution. 
Measures were taken to avoid agglomeration and to keep the plasmids evenly distributed in the 
solution during processing. The plasmid containing solution and the vials were kept cool with 
cooling elements.  
After filling, the vials for the homogeneity study, the stability studies, and the characterisation 
study were selected according to a random stratified sampling scheme from the entire batch. The 
vials were frozen either at (-20 ± 5) °C or at (-70 ± 10) °C.  
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3.3 Process control  
3.3.1 Identity confirmation 
The identity of the plasmid pIRMM-0099 was confirmed by restriction with the EcoRV enzyme. 
The circular plasmid was first analysed by DNA restriction analysis and agarose gel 
electrophoresis. The plasmid was restricted with HincII (Figure 2, lane 1), PvuII (Figure 2, lane 2) 
and XhoI (Figure 2, lane 3) and the resulting DNA bands were made visible on an agarose gel by 
UV after ethidium bromide staining. No other DNA bands than those expected could be observed. 
 
Figure 2: Restriction analysis of pIRMM-0099. Lane 1: pIRMM-0099 restricted with HincII (expected 
fragments: 4573 bp, 860 bp and 544 bp); Lane 2: pIRMM-0099 restricted with PvuII (expected fragments: 
2372 bp, 1965 bp, 709 bp, 598 bp, 195 bp and 132 bp; Lane 3: pIRMM-0099 restricted with XhoI (plasmid 
linearisation expected); Lane 4: DNA ladder (Invitrogen, Life Technologies Europe, Gent, BE).  
3.3.2 Purity of the plasmid extract 
In theory three different types of contaminants could be present in the plasmid extract: a) 
intermediate plasmids used for the assembly of pIRMM-0099, b) nucleic acids originating from 
host bacterial cells and c) non-nucleic acid contaminants.  
During the cloning process the bacterial cells could have been transfected with different 
populations of plasmids: pIRMM-0099 and one or more of the intermediate plasmids used the 
assembly of pIRMM-0099. The synthetic plasmids used in our cloning strategy (pUC18 and pCR 
2.1) have the same origin of replication (oriV from ColE1 plasmid) which allows them to replicate 
independently of the host chromosome. A bacterial cell however cannot replicate different 
plasmids with the same mechanism of replication. As a consequence only one plasmid will remain 
present in a bacterial clone while others are lost during cell division. As the plasmid production 
was started from a single colony, only one type of plasmid can be present in the plasmid extract 
[17]. To ensure that the plasmid production started from a single colony, one additional plating 
step was included. A single colony containing the pIRMM0099 was plated on a LB plate and from 
this plate one isolated colony was picked. 
After restriction with EcoRV and purification with the Qiaquick® gel extraction kit; the plasmid 
solution was analysed by gel electrophoresis. As there was no smear and/or RNA bands 
observed, it can be reasonably concluded that the plasmid preparation was not contaminated with 
large amounts of genomic DNA or RNA molecules from host bacterial cells. However, traces of 
genomic DNA or RNA molecules cannot be detected by gel electrophoresis.  
3054 bp 
2036 bp 
1018 bp 
1636 bp 
506 bp 
220 bp 
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The linearised plasmid was investigated by spectrophotometry to detect the presence of non-
nucleic acid contaminants like proteins, or chemical residues from nucleic acid extraction like 
phenol and guanidine. The UV absorbance of the plasmid in solution was measured at 230 nm 
(A230), 260 nm (A260) and 280 nm (A280). Taking into account the generally accepted mean 
extinction coefficient for double-stranded DNA at 260 nm and 280 nm, pure nucleic acid samples 
are expected to have an A260/A280 ratio of approximately 1.8 and an A260/A230 ratio of 
approximately 2.0 or higher [18]. The A260/A280 and A260/A230 ratios measured were 1.86 and 1.97 
respectively, indicating a sufficient DNA purity; however, such values do not exclude traces of 
contaminating proteins or chemical residues from nucleic acid extraction. 
Contamination of the stock solution of plasmid pIRMM-0099 with traces of nucleic acids for the 
host bacterial cells proteins may affect the DNA mass concentration measured by 
spectrophotometry and fluorometry and lead to an overestimation the copy number concentration 
of a plasmid in solution. However, such traces do not affect the dPCR measurements as the used 
primers and probes are highly specific for the targeted sequences and do not hybridise to other 
DNA fragments that could be present in the final plasmid preparation. A BLASTN 2.2.24+ analysis 
of the PCR primers did not reveal more than 70 % nucleic acid sequence identity with the 
genomic DNA of E. coli from the NCBI database (data not shown). Traces of or chemical residuals 
from nucleic acid extraction like phenol and guanidine might, however, inhibit the PCR reaction 
and lead to an underestimation of the copy number concentration of a plasmid solution. 
Inconsistencies between the estimations of the copy number concentration based on 
spectrophotometry and fluorometry and dPCR can therefore be used as an indication for the 
presence of contaminants in the plasmid solution. Table 1 shows the results obtained with these 
three different techniques. The measurement results and their standard deviations obtained for 
the copy number concentration estimates overlap.  
Table 1: The DNA mass concentrations and the estimated copy number concentrations obtained for the 
stock solution of linearised plasmid pIRMM-0099 using three different methods  
Method Number of 
replicates 
Mean 
CDNA ± s [ng/µL] 
Copy number concentration 
± s  [10 10cp/µL] 
Fluorometry (picogreen) 6 210 ± 2.8 (measured) 3.43 ± 0.05 (estimated) 
Spectrophotometry 3 214 ± 5.6 (measured) 3.49 ± 0.09 (estimated) 
dPCR 2 205 ±17.8 (estimated) 3.34 ± 0.29 (measured) 
 
Based on all these observations it can be reasonably concluded that there are no major 
contaminations present in the plasmid solution that might affect the behaviour of the plasmid in 
qPCR reactions.  
 
4  Assessment of homogeneity 
 
A key requirement for any reference material is the equivalence between the various units. In this 
respect, it is relevant whether the variation between units is significant compared to the 
uncertainty of the certified value. In contrast to that it is not relevant if this variation between units 
is significant compared to the analytical variation. Consequently, ISO Guide 34 requires RM 
producers to quantify the between unit variation. This aspect is covered in between-unit 
homogeneity studies. 
The within-unit heterogeneity does not influence the uncertainty of the certified value when the 
minimum sample intake is respected, but determines the minimum size of an aliquot that is 
representative for the whole unit. 
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4.1 Homogeneity assessment of the number of DNA fragments per plasmid 
The common certified value for ERM-AD623a, b, c, d, e and f is expressed as number of DNA 
fragments per plasmid. As each plasmid contains the three fragments, obtaining the certified 
value is independent of the number of plasmids contained in each vial and even a single plasmid 
would be sufficient to obtain the certified values. Homogeneity testing therefore needs to ensure 
that each plasmid contains both fragments once. The studies confirming the purity of the material 
are described in Section 3.3. 
4.2 Homogeneity assessment of the copy number concentration of the plasmid 
4.2.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified values of the CRM are 
valid for all vials of the material, within the stated uncertainty. The same analyses were performed 
for each concentration level of ERM-AD623.  
For the between-unit homogeneity test, 23 vials were selected using a random stratified sampling 
scheme covering the whole batch. For this, the batch was divided into 23 groups (with similar 
number of vials) and one vial was randomly selected from each group. The number of selected 
vials corresponds to approximately the cubic root of the total number of the produced vials. Each 
vial was measured three times with duplex qPCR amplifying the BCR-ABL b3a2 target and the 
ABL target as described in Section 1.3. The measurements were performed on three 96 wells 
plates and each plate contained a calibration curve and one measurement of every vial. This 
study design allows separation of a potential analytical drift (caused by a plate effect) from a trend 
in the filling sequence. The measurements were done under intermediate precision conditions, 
while evaluation was done under repeatability conditions as a correction was applied when a 
significant plate effect was present. Only the qPCR results of the BCR-ABL b3a2 target were used 
to assess the homogeneity of the material as the method repeatability of this target was the best.  
Analysis of variance (ANOVA) was performed to evaluate potential significant difference between 
the measurements performed on different PCR plates. Some significant (95 % confidence level) 
differences between the plates were visible, pointing at instability of the analytical system. As 
each vial is measured once on each of the three PCR plates, correction for this bias can improve 
the sensitivity of the subsequent statistical analysis through a reduction in analytical variation 
without masking potential between-unit heterogeneities. Therefore, the bias was corrected as 
shown below if the difference between the PCR plates was significant on at least a 95 % 
confidence level. 
id resultmeasuredresultcorrected    Equation 2 
With ii xxd /1     
id  correction factor for plate i  
1x  mean value measured for all vials on plate 1 
ix  mean value measured for all vials on plate i (2 or 3) 
Regression analyses were performed on the corrected datasets to evaluate potential trends in the 
filling sequence. No trends in the filling sequence were observed.  
The corrected dataset was tested for consistency using Grubbs outlier tests on a confidence level 
of 99 % on the individual results and the unit means. No outlying individual results and outlying 
unit means have been detected. The results of the measurements are shown in Annex B. 
Quantification of between-unit heterogeneity is most easily done by ANOVA, which can separate 
the between-unit variation (sbb) from the within-unit variation (swb). The latter is equivalent to the 
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method repeatability if the individual samples are representative for the whole unit. Evaluation by 
ANOVA requires unit means which follow at least a unimodal distribution and results for each unit 
that follow unimodal distributions with approximately the same standard deviations. Too few data 
are available for each unit to make a clear statement of the distribution of individual results. 
Therefore, it was checked whether all individual data follow a unimodal distribution using 
histograms and normal probability plots. Minor deviations from unimodality of the individual values 
do not grossly affect the estimate of between-unit standard deviations. The results of all statistical 
evaluations are given in Table 2.  
Table 2: Results of the statistical evaluation of the homogeneity study  
Outliers  
(confidence level 99 %) 
Distribution CRM Significant 
difference 
between plates 
(p < 0.05) 
Significant 
trend in filling 
sequence 
(p < 0.05) Individual results 
Unit means Individual 
results 
Unit means 
ERM-AD623a no  no none none normal unimodal 
ERM-AD623b yes (corrected) no none none normal  unimodal 
ERM-AD623c yes (corrected) no none none normal  unimodal 
ERM-AD623d yes (corrected) no none none normal unimodal 
ERM-AD623e yes (corrected) no none none unimodal unimodal 
ERM-AD623f no no none none normal unimodal 
 
One has to bear in mind that sbb,rel and swb,rel are estimates of the true standard deviations and 
therefore subject to random fluctuations. Therefore, the mean square between groups (MSbetween) 
can be smaller than the mean squares within groups (MSwithin), resulting in negative arguments 
under the square root used for the estimation of the between-unit variation, whereas the true 
variation cannot be lower than zero. In this case, u*bb, the maximum heterogeneity that could be 
hidden by method repeatability, was calculated as described by Linsinger et al. [19]. u*bb is 
comparable to the limit of detection of an analytical method, yielding the maximum heterogeneity 
that might be undetected by the given study setup.  
Method repeatability (swb,rel), between–unit standard deviation (sbb,rel) and u*bb,rel were calculated as  
y 
within
rel,wb
MS
s 
     Equation 3 
y
n
MSMS
s
withinbetween
rel,bb


    Equation 4 
y
νn
MS
u MSwithin
within
*
rel,bb
4
2

    Equation 5 
MSwithin mean square within a unit from an ANOVA  
MSbetween:  mean squares between-units from an ANOVA 
y  mean of all results of the homogeneity study 
n: mean number of replicates per unit 
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MSwithinν :  degrees of freedom of MSwithin  
 
The results of the evaluation of the between-unit variation are summarised in Table 3. In most 
cases, the uncertainty contribution for homogeneity was determined by the method repeatability. 
 
Table 3: Results of the homogeneity study 
CRM  swb,rel [%] sbb,rel [%] u*bb,rel [%] ubb,rel [%] 
ERM-AD623a 13.02 n.c. 3.57 3.57 
ERM-AD623b 10.93 n.c. 2.88 2.88 
ERM-AD623c 9.84 n.c. 2.59 2.59 
ERM-AD623d 9.38 n.c. 2.47 2.47 
ERM-AD623e 9.82 2.75 2.59 2.75 
ERM-AD623f 14.78 4.37 4.36 4.37 
n.c.: cannot be calculated as MSbetween < MSwithin  
The homogeneity study showed no outlying unit means or trends in the filling sequence. Therefore 
the between-unit standard deviation can be used as estimate of ubb. As u*bb sets the limits for the 
detection power of the study, the larger value of sbb and u*bb is adopted as uncertainty contribution 
to account for potential heterogeneity. 
4.2.2 Within-unit homogeneity and minimum sample intake 
Homogeneity/stability experiments were performed using a 5 µL sample intake. This sample 
intake gives acceptable repeatability, demonstrating that the within-unit heterogeneity does no 
longer contribute to analytical variation at this sample intake.  
 
5 Stability 
 
Time, temperature and radiation were regarded as the most relevant influences on stability of the 
materials. Stability testing is necessary to establish conditions for storage (long-term stability) as 
well as conditions for dispatch to the customers (short-term stability).  
The sensitivity of a DNA molecule to degradation is influenced by the GC content, the length of 
the strand and the buffer composition [20]. The three inserts are located on the same DNA strand 
and have a very similar GC content (54 % for the BCR-ABL b3a2 insert, 57 % for the BCR insert 
and 51 % for the GUSB insert). The stability of the three inserts is therefore considered to be 
identical. During the stability studies the copy number concentrations of the BCR-ABL b3a2 and 
the ABL PCR targets have been measured.  
The stability studies have been carried out using an isochronous design [21]. In that approach, 
samples are stored for a certain time at different temperature conditions. Afterwards, the samples 
are moved to conditions where further degradation can be assumed to be negligible ("reference 
conditions"), effectively "freezing" the degradation status of the materials. At the end of the 
isochronous storage, the samples are analysed simultaneously under repeatability conditions. 
Analysis of the material (after various exposure times and temperatures) under repeatability 
conditions greatly improves the sensitivity of the stability tests.  
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5.1 Short-term stability study 
For the short-term stability study, samples from the final batch have been stored at 4 °C for 0, 1, 2 
and 4 weeks. The reference temperature was set to -70 °C. Five vials per storage time were 
selected using a random stratified sampling scheme. From each vial three samples were 
measured by duplex qPCR. The measurements were performed on three PCR plates and one 
plate contained one sample of each vial. The measurements were done under intermediate 
precision conditions, while evaluation was done under repeatability conditions as a correction was 
applied when a significant plate effect was present. This study design allows distinguishing a 
potential analytical drift from a trend over storage time. Only the qPCR results of the BCR-ABL 
b3a2 target were used as the method repeatability of this target was the best. 
ANOVA was performed to evaluate potentially significant differences between the measurements 
performed on different PCR plates. Some significant (95 % confidence level) differences between 
the plates were detected, and results were corrected using Equation 2 as described in Section 
4.2.1.  
No outlying individual results were found using a Grubbs outlier test at a level of confidence of 
99 %.  
Furthermore, the data were plotted against storage time and regression lines of copy number 
concentration versus time were calculated. The slope of the regression lines was then tested for 
statistical significance (loss/increase due to shipping conditions). For all six concentrations of 
ERM-AD623, the slopes of the regression lines were not significantly different from zero (99 % 
confidence level).  
The results of the measurements are shown in Annex C. 
No technically unexplained outliers were observed and none of the trends with storage time was 
statistically significant on a 99 % confidence level. As a consequence of this, no uncertainty 
contribution has been added to the combined uncertainty budget for usts. 
The material was found stable at 4 °C for the period of 4 weeks. Nevertheless, the material is 
stored frozen and therefore freeze/thaw cycles should be kept at minimum. With this 
consideration, the material shall be shipped frozen on dry ice.  
5.2 Long-term stability study 
Before processing ERM-AD623 a, b, c, d, e, and f a smaller pilot batch was produced for each of 
the six CRMs. These pilot batches were processed in the same way as the final CRM batches. It 
was therefore possible to combine the data from three isochronous stability studies to assess the 
stability of the CRMs. Two of the studies were performed on the pilot batches and one on the final 
batches of ERM-AD623a, b, c, d, e, and f.  
In the first stability study, vials of the pilot batches have been stored at -20 °C for 0, 4, 8 and 12 
months. For the second study on the pilot batches the storage times were 0, 12, 18 and 24 
months at -20 °C. Vials of the final batches have been stored at -20 °C for 0, 3, 6 and 9 months. 
The reference temperature of all three studies was set at -70 °C.  
Within one study five vials were selected per storage time using a random stratified sampling 
scheme. From each vial, three samples were measured by duplex qPCR. The measurements 
were performed on three PCR plates and one plate contains one sample of each vial. This design 
allows separation of a potential analytical drift (plate effect) from a trend over storage time. The 
measurements were done under intermediate precision conditions, while evaluation was done 
under repeatability conditions as a correction was applied when a significant plate effect was 
present. Only the qPCR results of the BCR-ABL b3a2 target were used as the method 
repeatability of this target was the smallest. ANOVA was performed to evaluate potential 
significant difference between the measurements performed on different PCR plates. Some 
significant (95 % confidence level) differences between the plates were detected, and results were 
corrected using Equation 2 as described in Section 4.2.1.  
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The obtained data were first evaluated individually for each study. The results were screened for 
outliers using the single and double Grubbs test (99 % confidence level). Only for the third 
isochronous study of ERM-AD623c one outlying result was identified. As no technical reason for 
this outlier could be found all data were retained for statistical analysis. 
Furthermore, the data were plotted against storage time and regression lines of copy number 
concentration versus time were calculated. The slope of the regression lines was then tested for 
statistical significance (99 % confidence level). A positive trend was observed in the second 
isochronous study of ERM-AD623e. As the analyte cannot be created in the sample, a positive 
trend could only be due to degradation of the matrix. This, however, should be seen for all 
concentration levels, which is not the case. The observed trend was therefore regarded as a 
statistical artefact.  
Afterwards the results of the three isochronous studies have been combined to one long-term 
stability study as described in [22]. There was a measurement bias between the three studies. As 
study 2 has the longest storage times the results of the study 1 and 3 have been normalised to the 
results of study 2 using the correction factor d as calculated in Equation 6. The relative uncertainty 
of these corrections ud, rel is calculated with Equation 7. 
ixxd /2       Equation 6 
2x  mean measurement result of study 2 
ix  mean measurement result of study i (1 or 3) 
2
2
2
2
,,
11 RSD
n
RSD
n
u i
i
relid      Equation 7 
relidu ,,  relative uncertainty of the correction of study i  
RSDi relative standard deviation of all results in study i 
RSD2 relative standard deviation of all results in study 2 
ni number of data points is study i 
n2 number of data points in study 2 
 
The normalised data were plotted against storage time and regression lines of copy number 
concentration versus time were calculated. The slope of the regression lines was then tested for 
statistical significance (loss/increase due to storage conditions). For all six CRMs the slopes of the 
regression lines were not significantly different from zero (99 % confidence level). The significant 
trend observed in study 2 of ERM-AD623e is no longer present in the combined stability study. 
These results confirm that the observed trend for the individual study is a statistical artefact.  
The results of the measurements are shown in Annex D.  
Based on these measurements, it can be concluded that the plasmid solutions can be stored at 
-20 °C. 
5.3 Estimation of uncertainties 
Due to the intrinsic variation of measurement results, no study can rule out degradation of 
materials completely, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation that could be hidden by the method repeatability, 
i.e. to estimate the uncertainty of stability. This means, even under ideal conditions, the outcome 
of a stability study can only be "degradation is (0 ± x) % per time".  
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The uncertainty of stability during dispatch was not considered as the samples will be shipped on 
dry ice and the storage temperature is -20°C ± 5°C. 
The uncertainty of stability during dispatch was estimated as described in [21] and [22]. For this 
approach, the uncertainty of the linear regression line with a slope of zero is calculated. The 
uncertainty contribution ults is then calculated as the product of the chosen shelf life and the 
uncertainty of the regression lines. As the long-term stability study is a combined study of two 
isochronous studies the uncertainty of the correction (ud) should also be taken in account 
(Equation 8). 
 
  sli
yx
lts t
tt
RSD
u 

  2
*      Equation 8 
RSDx*y relative standard deviation of the estimate 
ti time point for each replicate 
t  mean of all time points  
tsl proposed shelf life (two years at -20 °C) 
 
The standard error on the estimate sx*y should be calculated with Equation 9 
3,,
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3
1,,
12
12
* reldreldpooledyx unn
nu
nn
nRSDRSD     Equation 9 
RSD2pooled: relative standard deviation of the combined stability studies 
n1 number of measurement results in study 1 
n2 number of measurement results in study 2 
n3 number of measurement results in study 3 
ud,rel,1 uncertainty of the correction of study 1 
ud,rel,3 uncertainty of the correction of study 3 
 
The uncertainty contribution related to the stability during storage (ults,rel) was estimated for 24 
months and describes the possible degradation at -20 °C. The results of these evaluations are 
summarised in Table 4. 
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Table 4: Uncertainties of stability during storage. ults,rel was calculated for a storage temperature of -20 °C 
and 24 months 
CRM ults,rel 
[%] 
ERM-AD623a 2.75 
ERM-AD623b 2.21 
ERM-AD623c 2.81 
ERM-AD623d 2.11 
ERM-AD623e 2.43 
ERM-AD623f 3.83 
 
The uncertainty of the long-term stability has been considered in the combined uncertainty 
(Section 7.2). After the certification campaign, the material will be subjected to IRMM's regular 
stability monitoring programme to control its further stability. 
5.4 Stability after freeze/thaw cycles 
Since the minimum sample intake is 5 µL, one experiment measuring BCR-ABL b3a2 and one 
control gene by simplex qPCR requires at least 30 µL. One vial contains approximately 600 µL 
and can therefore be used for less than 20 experiments. The storage temperature is -20 °C and 
repeated use of the CRM will require repeated freeze/thaw cycles. In these stability studies the 
effect of repeated freeze/thaw cycles is investigated.  
These stability studies have been carried out using an approach similar to the isochronous design. 
Vials from the pilot batches from ERM-AD623a, ERM-AD623c and ERM-AD623f have been used 
to perform these studies. For each of these three concentrations five vials were exposed to 0, 5, 
10 and 20 freeze/thaw cycles and moved to the reference condition (-70 °C) afterwards.  
Each vial was measured three times with duplex real time PCR as described in Section 1.3. The 
measurements were performed on three 96 wells plates and each plate contained a calibration 
curve and one sample of every vial. This study design allows separation of a potential analytical 
drift (caused by a plate effect) from a trend generated by the freeze/thaw cycles. The 
measurements were done under intermediate precision conditions, while evaluation was done 
under repeatability conditions as a correction was applied when a significant plate effect was 
present. The qPCR results of the BCR-ABL b3a2 target were used as the method repeatability of 
the target was the smallest. 
ANOVA was performed to evaluate potential significant differences between the measurements 
performed on different PCR plates. Some significant (95 % confidence level) differences between 
the plates were detected, and results were corrected using Equation 2 as described in Section 
4.2.1. No outlying individual results were found using Grubbs outlier tests (99 % confidence level). 
Furthermore, the data were plotted against the number of freeze/thaw cycles and regression lines 
of copy number concentration versus number of freeze/thaw cycles were calculated. The slope of 
the regression lines was then tested for statistical significance (loss/increase due to freezing 
thawing). For the test batches of ERM-AD623c and ERM-AD623f the slope of the regression lines 
were not significantly different from zero (99 % confidence level). For the test batch of ERM-
AD623a the slope of the regression line was significantly different from zero (99 % confidence 
level). Closer investigation of the results for the test batch of ERM-AD623a showed that there was 
no significant degradation after 5 and 10 cycles. However, the results obtained for the vials that 
were exposed to 20 freeze/thaw cycles were significantly lower. The results are shown in Annex 
E.  
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Although this degradation was only observed for one concentration level, precautions should be 
taken and the CRMs should not be exposed to more than ten freeze/thaw cycles. 
6 Characterisation 
 
The material characterisation is the process of determining the property value of a reference 
material. 
6.1 Characterisation study for the number of DNA fragments per plasmid 
The number of DNA fragments per plasmid is defined by the structural identity of the plasmid i.e. 
the sequence. Dideoxy terminator sequencing (or Sanger sequencing) was used to determine the 
sequence of the plasmid.  
6.1.1 Study set up  
Two laboratories were selected based on criteria that comprised both technical competence and 
quality management aspects. Each participant was required to operate a quality system and to 
deliver documented evidence of its laboratory proficiency in the field dideoxy terminator 
sequencing by submitting results for intercomparison exercises or method validation reports. 
Having a formal accreditation was not mandatory, but meeting the requirements of ISO/IEC 17025 
was obligatory.  
Each laboratory received one vial containing the circular pIRMM-0099 plasmid dissolved in T1E0.01 
buffer at a concentration of approximately 150 ng/µL. These vials were set aside during the 
processing process as described in Section 3.2.1. The laboratories were requested to perform 
double stranded sequencing of an entire circular plasmid by using primer walking. Sequences 
were generated using the BigDye® Terminator chemistry version 3.1 (ABI). The sequence 
reactions were analysed on ABI3730 capillary sequencers.    
6.1.2 Results 
Each laboratory provided a full sequence of the pIRMM-0099 plasmid. Comparison of both 
obtained sequences showed that they were identical. The laboratories also provided the 
sequence quality values of each nucleotide. This quality value QV is a transformed estimate of the 
probability of correctness (1-probability of error) and defined by the following equation: 
)(log10 10 ePQV       Equation 10 
Pe estimated error probability of a base 
The sequence results generated by the first laboratory had the best quality. Each base pair within 
the sequence generated had a quality score of at least 67 corresponding to an error probability of 
less than 1/5000000. Due to the fact that most of the base pairs had an even higher quality score 
and the calculated cumulative calculated cumulative error of the entire plasmid sequence 
(5970 bp) is 1/718013375. Based on the Poisson distribution and the length of each cloned DNA 
fragment, the probability of one sequencing error per DNA fragment can be calculated. This 
probability is less than 0.0002 % for each cloned fragment. 
Within the sequence generated by the second laboratory, each base pair had a quality score of at 
least 38. These results were considered as confirmatory results.  
The sequences of the fragments were also compared with the consensus sequences of the 
transcripts of GUSB, BCR and ABL available in the GenBank database (NCBI, NIH, Bethesda, 
MD, US). Two differences were observed between the consensus sequences from Genbank and 
the sequences of the fragments present in pIRMM-0099. These differences correspond to two 
known single nucleotide polymorphisms (SNPs) present in the SNP database (dbSNP, NCBI, 
http://www.ncbi.nlm.nih.gov/projects/SNP). The DNA fragment of the BCR-ABL b3a2 transcript 
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contains the G allele of the SNP with reference number rs140504 while the consensus sequence 
in the NCBI database contains the A allele. Within the DNA fragment of the BCR transcript, the T 
allele of SNP rs11558697 is present while in the consensus sequence the C allele is present. 
These SNP can also be present in patients' samples and they should be taken in account when 
using primers or probes located at these positions. The effect of the presence of the SNPs on the 
PCR efficiency can be tested by performing cross-over experiment as described in [23]. Otherwise 
a mixture of two oliginucleotides, each contain one allele of the SNP, should used as primer or 
probe. 
The alignment of the sequences (Annex F) shows that each of the three fragments is present 
once in the plasmid. As a clear consequence, the structurally defined ratio between the number of 
DNA fragment specific for BCR-ABL b3a2 transcript and the DNA fragments specific for BCR and 
GUSB is 1.  
6.1.3 Confirmatory measurements  
Digital PCR measurements were performed to confirm the structurally defined ratio between the 
numbers of DNA fragment specific for BCR-ABL b3a2 transcript and the DNA fragments specific 
for BCR and GUSB. Target sequences located on the BCR-ABL b3a2 fragment and the GUSB 
fragment were amplified in a duplex dPCR reaction using primers and probes and PCR conditions 
described in [5, 6]. The primers and probes and PCR conditions described in [11] were used to 
amplify target sequences located on the BCR-ABL b3a2 fragment and the BCR fragment in a 
duplex dPCR reaction. For each plasmid concentration of ERM-AD623 one vial was measured on 
five panels of a digital array. The value of 1 was confirmed for both ratios. Results are shown in 
Table 5. 
 
Table 5: The results of duplex dPCR measurements to confirm the structurally defined copy number ratios 
CRM Copy number ratio 
BCR-ABL b3a2/GUSB ± s  
Copy number ratio 
BCR-ABL b3a2 /BCR ± s  
ERM-AD623a 1.015 ± 0.017 1.000 ± 0.013 
ERM-AD623b 0.994 ± 0.016 1.019 ± 0.015 
ERM-AD623c 0.990 ± 0.012 1.012 ± 0.033 
ERM-AD623d 1.008 ± 0.022 0.994 ± 0.021 
ERM-AD623e 1.000 ± 0.018 1.005 ± 0.020 
ERM-AD623f 0.989 ± 0.074 0.966 ± 0.050 
 
6.2 Characterisation study for the copy number concentration of the plasmid 
The material characterisation was based on an intercomparison of expert laboratories. The 
certified value for the copy number concentration of the plasmid of the six plasmid dilutions was 
determined by dPCR measurements performed by three different laboratories. All participants 
used the BioMark system (Fluidigm) and the 12.765 digital arrays to perform the measurements. 
This approach aims at randomisation of laboratory bias, which reduces the combined uncertainty. 
6.2.1 Study set up 
Three laboratories were selected based on criteria that comprised both technical competence and 
quality management aspects. Each participant was required to operate a quality system and to 
deliver documented evidence of its laboratory proficiency in the field of dPCR measurements by 
previous publications. Having a formal accreditation was not mandatory, but meeting the 
requirements of ISO/IEC 17025 was obligatory. Where measurements are covered by the scope 
of accreditation, the accreditation number is stated in the list of participants (Section 2). 
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Each laboratory received six vials of each plasmid concentration of ERM-AD623 and was 
requested to provide six independent results, one result per vial. Vials for material characterisation 
were selected using a random stratified sampling scheme and covered the whole batch. Each of 
the six vials from one CRM had to be diluted and measured on a different day and on different 
digital array to ensure intermediate precision conditions. 
All laboratories used the BioMark system (Fluidigm) and the 12.765 Digital arrays to perform the 
measurements. The BCR-ABL b3a2 target and the ABL target (both located on the BCR-ABL 
b3a2 transcript fragment) were amplified in a duplex PCR reaction as described in Section 1.3. 
Each sample mix was analysed on five panels of one digital array. The results of both the BCR-
ABL b3a2 and the ABL target were used to demonstrate the absence of a bias which might be 
due to one specific set of primers and probe. The mean value of both PCR targets (n = 10) 
obtained was considered as one independent measurement result.  
6.2.2 Results 
The characterisation campaign resulted in 18 independent measurement results per CRM. The 
obtained data were first checked for compliance with the requested analysis protocol and for their 
validity based on technical reasons. The following criteria were considered during the evaluation:  
 compliance with the analysis protocol: sample preparations and measurements performed 
on six different days 
 correctness of the dilutions steps: all dilutions steps had to be prepared gravimetrically and 
masses had to be recorded  
 visual check if there was no air bubble present in the panels  
 each independent measurement result should be based on the results of 5 panels  
Based on the above two datasets were rejected as not technically valid: one for ERM-AD623a and 
one for ERM-AD623f. In both cases there was an air bubble present in one of the panels.  
All accepted results of the participants, grouped per CRM, are displayed in tabular form in Annex 
G.  
Statistical analyses were performed to identify the major source of variation in this 
characterisation study. One way ANOVA analyses were performed to calculate the standard 
deviation between independent measurements performed within one laboratory (swithin labs), the 
standard deviation between laboratories (sbetween labs) and the standard deviation of all independent 
measurements (sall measurements). Standard deviations between all independent measurements are 
considerably larger than the standard deviation within laboratories. One way ANOVA analysis also 
showed that there is no significant difference between the results obtained by the different 
laboratories (95 % confidence level). The results of these ANOVA analyses are summarised in 
Table 6. Moreover, the standard deviation between all measurements from this intercomparison is 
very similar to the standard deviation between measurements obtained during the method 
validation performed within one laboratory (IRMM). The standard deviation between 
measurements from the in-house method validation was 14.71 %. 
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Table 6: Statistical analyses to identify the major source of variation in the characterisation study 
CRM Laboratory number swithin lab, rel  [%] sbetween labs, rel [%] sall measurements, rel [%] 
1 12.66 
2 10.11 ERM-AD623a 
3 16.88 
n.c. 13.03 
1 17.86 
2 11.64 ERM-AD623b 
3 14.17 
5.03 15.12 
1 9.46 
2 12.95 ERM-AD623c 
3 11.73 
6.25 12.68 
1 6.40 
2 11.61 ERM-AD623d 
3 10.15 
6.70 11.20 
1 11.40 
2 11.43 ERM-AD623e 
3 8.72 
8.22 12.81 
1 15.43 
2 18.72 ERM-AD623f 
3 6.68 
5.78 15.96 
n.c.: cannot be calculated as MSbetween < MSwithin  
 
This information shows that the variations between independent measurements have a larger 
impact than the variations between laboratories. Each of the 18 independent measurements was 
therefore considered as a separated data set.  
The datasets accepted on technical grounds were tested for normality of dataset means using 
kurtosis/skewness tests and normal probability plots and were tested for outlying means using the 
Grubbs test and using the Cochran test for outlying standard deviations (both at 99 % confidence 
level). The dataset means follow normal distributions. None of the data contains outlying means. 
The datasets are therefore consistent and the mean of independent measurement results is a 
good estimate of the true value.  
The uncertainty for the characterisation exercise was estimated as the relative standard 
uncertainty of the independent measurement results, i.e. 
p
s tsmeasuremenall with s the relative standard 
deviation of the independent measurement results and p the number of technically valid 
independent measurements. The results of these evaluations are shown in Table 7. 
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Table 7: Statistical evaluation of the technically accepted data sets for ERM-AD623. p number of technically 
valid independent measurements, s standard deviation, uchar uncertainty related to the characterisation 
study 
Copy number concentration of the plasmid 
Outliers Statistical parameters  CRM p 
Means Variances 
Normally 
distributed Mean 
[cp/µL] 
s 
[cp/µL] 
uchar 
[cp/µL] 
uchar, rel 
[%] 
ERM-AD623a 17 none none yes 1081264 146173 35452 3.28 
ERM-AD623b 18 none none yes 107706 16343 3852 3.58 
ERM-AD623c 18 none none yes 10321 1317 310 3.01 
ERM-AD623d 18 none none yes 1018 115 27 2.66 
ERM-AD623e 18 none none yes 103.5 13.5 3.2 3.06 
ERM-AD623f 17 none none yes 9.96 1.75 0.42 4.28 
 
7 Value Assignment 
 
7.1 Copy number ratio of specific DNA fragments within the plasmid  
The plasmid calibrant is characterised for the copy numbers of each of the three specific DNA 
fragments per plasmid i.e. the BCR-ABL b3a2 transcript fragment, the BCR transcript fragment 
and the GUSB transcript fragment. Sequence analysis showed that three cloned DNA fragments 
were present as a single copy in the plasmid and that their sequence was correct.  
Based on the sequence identity the copy number ratios BCR-ABL b3a2 transcript 
fragment/plasmid, GUSB transcript fragment/plasmid and BCR transcript fragment/ plasmid are 1. 
The sequence identity of the plasmid was determined by two independent laboratory analyses 
which provided exactly the same results. The DNA sequencing was performed by forward and 
backward sequencing. The uncertainty on sequencing under those conditions can be considered 
as negligible.    
 
Table 8: Certified values and their uncertainties for the number of specific DNA fragments per plasmid 
Specific DNA fragment Number of fragment per plasmid Uncertainty  
BCR-ABL b3a2 transcript 1 negligible 
BCR transcript 1 negligible 
GUSB transcript 1 negligible 
 
Based on the sequence identity and the purity assessment the theoretical copy number ratios 
BCR-ABL b3a2 transcript fragment/ GUSB transcript fragment and BCR-ABL b3a2 transcript 
fragment/BCR transcript fragment are 1. These copy number ratios are confirmed by dPCR 
measurements. 
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7.2 The copy number concentration of the plasmid 
The unweighted mean of the accepted datasets as shown in Section 6 was assigned as certified 
value for the copy number concentration of the plasmid. 
The assigned uncertainty consists of uncertainties related to characterisation, uchar, potential 
between-unit heterogeneity, ubb and potential degradation during transport (usts) and long-term 
storage, ults. These different contributions were combined to estimate the expanded, relative 
uncertainty of the certified value (UCRM, rel) with a coverage factor k as  
2
rel lts,
2
rel bb,
2
rel char,rel CRM, uuukU      Equation 11 
uchar was estimated as described in Section 6  
ubb was estimated as described in Section 4 
ults was estimated as described in Section 5.  
Because of the sufficient numbers of the degrees of freedom of the different uncertainty 
contributions, a coverage factor k of 2 was applied to obtain the expanded uncertainties.  
The certified values and their uncertainties are summarised in Table 9. 
 
Table 9: Certified values and their uncertainties for the copy number concentration of the plasmid 
CRM 
Copy number 
concentration of the 
plasmid [cp/µL] 
uchar, rel 
[%] 
ubb, rel 
[%] 
ults, rel 
[%] 
UCRM, rel  
[%] 
UCRM  
[cp/µL] 
ERM-AD623a 1.08×106 3.28 3.57 2.75 11.15 0.13×106 
ERM-AD623b 1.08×105 3.58 2.88 2.21 10.19 0.11×105 
ERM-AD623c 1.03×104 3.01 2.59 2.81 9.73 0.10×104 
ERM-AD623d 1.02×103 2.66 2.47 2.11 8.40 0.09×103 
ERM-AD623e 1.04×102 3.06 2.75 2.43 9.56 0.10×102 
ERM-AD623f 10.0 4.28 4.37 3.83 14.42 1.5 
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8 Metrological traceability  
 
8.1 Metrological traceability  
8.1.1. Copy number ratio of specific DNA fragments within the plasmid  
The sequence identity of the pIRMM-0099 plasmid is structurally defined and independent of the 
measurement method. Dideoxy terminator sequencing was used to determine the sequence 
identity of plasmid pIRMM-0099. Dideoxy terminator sequencing is a method of high metrological 
order as it does not require a calibrant and the obtained results have a very low uncertainty. 
Based on this sequence identity the copy number ratio of the specific DNA fragments per plasmid 
was determined. This copy number ratio was confirmed by an independent method, i.e. dPCR. 
The value of the copy number ratio of the specific DNA fragment per plasmid is traceable to the 
SI. 
8.1.2 Copy number concentration of the plasmid 
The copy number concentration of the plasmid is a method-defined measurand and has been 
obtained by PCR using the primers and probe set and the PCR conditions as described in Annex 
A. The value of the copy number concentration of the plasmid is traceable to SI. Traceability of the 
obtained results is based on the traceability of all relevant input factors. Instruments in individual 
laboratories were verified and calibrated with tools ensuring traceability to the SI. Consistency in 
the intercomparison demonstrates that all relevant input factors were covered. As the assigned 
values are combinations of agreeing results individually traceable to the SI, the assigned quantity 
values themselves are traceable to the SI as well. 
 9 Commutability  
 
Many measurement procedures include one or more steps, which are selecting specific (or 
specific groups) of analytes from the sample for the subsequent steps of the whole measurement 
process. Often the complete identity of these 'intermediate analytes' is not fully known or taken 
into account. Therefore, it is difficult to mimic all the analytically relevant properties of real samples 
within a CRM. The degree of equivalence in the analytical behaviour of real samples and a CRM 
with respect to various measurement procedures (methods) is summarised in a concept called 
'commutability of a reference material'. There are various definitions expressing this concept. For 
instance, the CSLI Guideline C-53A [24] recommends the use of the following definition for the 
term commutability: 
"The equivalence of the mathematical relationships among the results of different measurement 
procedures for an RM and for representative samples of the type intended to be measured." 
The commutability of a CRM defines its fitness for use and, thus, is a crucial characteristic in case 
of the application of different measurement methods. When commutability of a CRM is not 
established in such cases, the results from routinely used methods cannot be legitimately 
compared with the certified value to determine whether a bias does not exist in calibration, nor 
can the CRM be used as a calibrator.  
This set of CRM is used to calibrate the qPCR reaction targeting the BCR-ABL b3a2 transcript. 
The plasmid DNA present in these calibrant is different from the cDNA obtained from patient 
samples. However, based on the traceability chain described above, as well as on additional 
practical reasons, which include full sequence characterisation, reproduction of additional batches 
of calibrant and availability, ERM-AD623 is selected as the calibrant of choice to be used for the 
calibration of the qPCR reactions. 
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A limited commutability study was performed to test the performance of this set of plasmid 
solutions using different methods. Nine laboratories were selected on the basis of proven 
experience and quality management systems in place. The laboratories were asked to perform 
these measurements with the simplex qPCR method(s) that they routinely use to determine the 
ratio of BCR-ABL b3a2 transcript to the control gen transcript. An overview of the different 
methods used is given in Annex H. 
Per method used, laboratories received two sets of the six plasmid solutions of ERM-AD623 and 
two dilutions of cDNA sample. This cDNA sample was extracted from K562 cells and diluted to 
two different concentrations: Based on the results of one dPCR measurement dilution 1 had an 
estimated BCR-ABL b3a2 transcript copy number concentration of 3.6*104 ± 0.3*104 cp/µL and 
dilution 2 of 1.3 *103 ± 0.04 *103 cp/µL.  
From each set of plasmid solution eight calibration curves should be measured: four for the BCR-
ABL b3a2 transcript and four for the control gene transcript. The two cDNA solutions were also 
measured and their copy number ratio of BCR-ABL b3a2/control gene was determined using the 
different calibration curves. In total the results of each laboratory for each method consist of the 
following: eight calibration curves for both the BCR-ABL b3a2 transcript and the control gene 
transcript and eight measured copy number ratio BCR-ABL b3a2/ control gene for two cDNA 
solutions.  
The obtained data were first checked for compliance with the requested analysis protocol and for 
their validity based on technical reasons. Reasons for exclusion were: too much variation between 
triplicates, the control gene and the BCR-ABL b3a2 not measured on the same PCR plate, and 
degradation of the cDNA solution.  
The calibration curves were evaluated for their slope and coefficient of determination (r2). The 
slope should be between -3.00 and -3.60 and the r2 should be above 0.99. In total, there were 171 
accepted calibration curves: 84 for BCR-ABL b3a2, 36 for ABL, 23 for BCR and 28 for GUSB. 
Only 3 calibration curves were rejected because their slope was outside the range of -3.00 to -
3.60. Two of them had a slope of -3.61 and one had a slope of -3.62. All calibration curves had an 
r2 above 0.993.  
Only the accepted calibration curves were used to determine the copy number ratios BCR-ABL 
b3a2/ control gene of the two cDNA solutions and the results are shown in Annex H. The relative 
standard deviation between the mean copy number ratio measured by the different laboratories 
for the two cDNA solutions were 8 % for the ratio BCR-ABL b3a2 /BCR, 14 % for the ratio BCR-
ABL/ABL and 18 % for the ratio BCR-ABL b3a2/GUSB. These differences are within the expected 
variability of qPCR measurements as the RSD of an accurate qPCR method can be up to 30 %.  
Based on the results of this commutability study it was concluded that this set of six CRMs with 
different plasmid concentrations can be used to calibrate different qPCR measurements 
determining the copy number ratio of the BCR-ABL b3a2 transcript to three control genes i.e. 
BCR, ABL and GUSB.  
The user should however be aware, that the plasmid calibrant cannot be used to control the 
sample preparation steps before the qPCR including the reverse transcription step. Therefore 
additional matrix reference material should be used to control the whole measurement procedure 
of the patient samples. Secondary reference materials calibrated with the "WHO International 
Genetic Reference Panel for the quantification of BCR-ABL translocation" can be used for this 
purpose. The matrix materials should be cell line mixtures which have the same analytical 
behaviour as patient samples [25].  
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 10 Instructions for use 
 
10.1 Storage conditions 
The materials shall be stored at -20 °C ± 5 °C prior to use.  
Under the condition that contaminations have been excluded, the solutions can be used for 
several experiments. The material should however not pass more than 10 freeze/thaw cycles. The 
material can also be stored at 4°C for 4 weeks as it was verified that changes to the certified 
concentration observed during that period are not significant. It is advisable to close the vial with 
the original screw cap after use. The plasmid containing solution should not be exposed to direct 
sun light. 
Please note that the European Commission cannot be held responsible for changes that happen 
during storage of the material at the customer's premises, especially of opened samples. 
10.2 Safety and protection for the environment 
The usual laboratory safety measures apply. 
10.3 Preparation and use of the material  
To make the plasmid solutions ready for use, the content of the vials has to be thawed completely 
and mixed gently by inverting the vial several times. The plasmid containing vials should be 
opened and handled under a laminar flow to reduce the risk of contamination. 
10.4 Minimum sample intake 
The minimum sample intake representative is 5 µL.  
10.5 Use of the certified value 
ERM-AD623 is only intended to be used for the calibration of quantitative real time PCR (qPCR) 
methods for the measurement of the copy number ratio of the BCR-ABL b3a2 transcript to one of 
the following control genes BCR, ABL or GUSB. A limited commutability study has shown that 
ERM-AD623 can be used to calibrate different qPCR methods targeting BCR-ABL b3a2. A list of 
the qPCR methods can be found in Annex H. For other targets such as the BCR-ABL b2a2 
transcript, the suitability of ERM-AD623 has to be verified.  
This set contains six concentrations which should be used to construct the calibration curve for 
both the BCR-ABL b3a2 transcript and the control gene. The contribution of this calibrant to the 
measurement uncertainty on this ratio is negligible.  
In addition, the calibration curve is also used to estimate the absolute copy number concentration 
of the control gene in the patient samples. In this case, the uncertainty of the certified value 
should be taken into account. 
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Annexes 
Annex A: Description of the PCR method used as qPCR and dPCR to determine the copy 
number concentration of the plasmid 
Table A1: Primers and probes used to amplify the BCR-ABL and the ABL target in a duplex PCR 
reaction 
PCR 
target 
Primer/ probe Sequence Concentration 
in PCR reaction  
[nM] 
Amplicon 
size 
Forward primer 5'-TCCGCTGACCATCAAYAAGGA-3' 300  
Reverse primer 5'-CACTCAGACCCTGAGGCTCAA-3' 300 BCR-
ABL 
Probe 5'-(6-VIC)-CCCTTCAGCGGCCAGTAG 
CATCTGA-(MGB)-3' 
200 
149 
Forward primer 5'-TGGAGATAACACTCTAAGCATAAC 
TAAAGGT-3' 
300 
Reverse primer 5'-GATGTAGTTGCTTGGGACCCA-3' 300 ABL 
Probe 5'-(6-FAM)-CCATTTTTGGTTTGGGCTT 
CACACCATT-(TAMRA)-3' 
200 
122 
 
Table A2: Thermal cycling protocol used for the duplex PCR reaction amplifying the BCR-ABL and 
ABL target 
Name Phase Time [seconds] Temperature [°C] Repeats 
UNG 120 50 UNG and Hot start 
Hot start 600 95 
1 
Denaturation 15 95 PCR cycles 
 Annealing 60 60 
50 
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Annex B: Results of the homogeneity measurements 
 
Figure B1: Homogeneity for the copy number concentration of plasmid in ERM-AD623a. The error bars 
represent the standard deviation from 3 replicates. 
 
Figure B2: Homogeneity for the copy number concentration of the plasmid in ERM-AD623b. The error bars 
represent the standard deviation from 3 replicates. 
 
Figure B3: Homogeneity for the copy number concentration of the plasmid in ERM-AD623c. The error bars 
represent the standard deviation from 3 replicates 
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Figure B4: Homogeneity for the copy number concentration of the plasmid in ERM-AD623d. The error bars 
represent the standard deviation from 3 replicates 
 
Figure B5: Homogeneity for the copy number concentration of the plasmid in ERM-AD623e. The error bars 
represent the standard deviation from 3 replicates 
 
Figure B6: Homogeneity for the copy number concentration of the plasmid in ERM-AD623f. The error bars 
represent the standard deviation from 3 replicates 
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Annex C: Results of the short-term stability studies 
 
Figure C1: Short-term stability for the copy number concentration of the plasmid in ERM-AD623a. 
 
Figure C2: Short-term stability for the copy number concentration of Plasmid in ERM-AD623b. 
 
Figure C3: Short-term stability for the copy number concentration of the plasmid in ERM-AD623c. 
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Figure C4: Short-term stability for the copy number concentration of the plasmid in ERM-AD623d. 
 
Figure C5: Short-term stability for the copy number concentration of the plasmid in ERM-AD623e. 
 
Figure C6: Short-term stability for the copy number concentration of the plasmid in ERM-AD623f. 
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Annex D: Results of the long-term stability measurements 
 
Figure D1: Long-term stability of the copy number concentration of the plasmid in ERM-AD623a.  
 
Figure D2: Long-term stability of the copy number concentration of the plasmid in ERM-AD623b.  
 
Figure D3: Long-term stability of the copy number concentration of the plasmid in ERM-AD623c.  
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Figure D4: Long-term stability of the copy number concentration of the plasmid in ERM-AD623d.  
 
Figure D5: Long-term stability of the copy number concentration of the plasmid in ERM-AD623e.  
 
Figure D6: Long-term stability of the copy number concentration of the plasmid in ERM-AD623f. 
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Annex E: Results of the freeze/thaw stability study 
 
Figure E1: Stability of the copy number concentration of the plasmid in ERM-AD623a after several 
freeze/thaw cycles. 
 
Figure E2: Stability of the copy number concentration of the plasmid in ERM-AD623c after several 
freeze/thaw cycles. 
 
Figure E3: Stability of the copy number concentration of the plasmid in ERM-AD623f after several 
freeze/thaw cycles. 
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Annex F: Alignment of the results obtained by sequence analysis and the published 
consensus sequences 
Lab1 5970 atctgcagaattcggcttgtaaacgggctgttttccaaacattgtgacttggctactgagtggggatacctggtttcatt 
Lab2    1 atctgcagaattcggcttgtaaacgggctgttttccaaacattgtgacttggctactgagtggggatacctggtttcatt 
GUSB   813 ------------------gtaaacgggctgttttccaaacattgtgacttggctactgagtggggatacctggtttcatt 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5890 ggcaatcttccagtatctctctcgcaaaaggaacgctgcactttttggttgtctctgccgagtgaagatcccctttttat 
Lab2   81 ggcaatcttccagtatctctctcgcaaaaggaacgctgcactttttggttgtctctgccgagtgaagatcccctttttat 
GUSB   751 ggcaatcttccagtatctctctcgcaaaaggaacgctgcactttttggttgtctctgccgagtgaagatcccctttttat 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5810 tccccagcactctcgtcggtgactgttcagtcatgaaatcggcaaaattccaaatgagctctccaaccacgtattttctg 
Lab2  161 tccccagcactctcgtcggtgactgttcagtcatgaaatcggcaaaattccaaatgagctctccaaccacgtattttctg 
GUSB  671 tccccagcactctcgtcggtgactgttcagtcatgaaatcggcaaaattccaaatgagctctccaaccacgtattttctg 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5730 cgtttttgatccagacccagatggtactgctctagcagacttttctggtactcttcagtgaacatcagaggtggatcctg 
Lab2  241 cgtttttgatccagacccagatggtactgctctagcagacttttctggtactcttcagtgaacatcagaggtggatcctg 
GUSB  591 cgtttttgatccagacccagatggtactgctctagcagacttttctggtactcttcagtgaacatcagaggtggatcctg 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5650 gtgaaaccctgcaatcgtttctgctccatactcgctctgaataatgggcttctgatacttcttataccagttctcaaact 
Lab2  321 gtgaaaccctgcaatcgtttctgctccatactcgctctgaataatgggcttctgatacttcttataccagttctcaaact 
GUSB   511 gtgaaaccctgcaatcgtttctgctccatactcgctctgaataatgggcttctgatacttcttataccagttctcaaact 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5570 gggtggccagctgcagctgaatcaactccaggtgcccgtagtcgtgataccaagagtagtagctgttcaaacagatcaca 
Lab2  401 gggtggccagctgcagctgaatcaactccaggtgcccgtagtcgtgataccaagagtagtagctgttcaaacagatcaca 
GUSB   431 gggtggccagctgcagctgaatcaactccaggtgcccgtagtcgtgataccaagagtagtagctgttcaaacagatcaca 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5490 tccacatacggagcccccttgtctgctgcatagttagagttgctcacaaaggtcacaggccgggaggggtccaaggattt 
Lab2  481 tccacatacggagcccccttgtctgctgcatagttagagttgctcacaaaggtcacaggccgggaggggtccaaggattt 
GUSB   351 tccacatacggagcccccttgtctgctgcatagttagagttgctcacaaaggtcacaggccgggaggggtccaaggattt 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5410 ggtgtgagcgatcaccatcttcaagtagtagccagcagattctaggtgggacgcaggctcgttggccacagaccacatca 
Lab2  561 ggtgtgagcgatcaccatcttcaagtagtagccagcagattctaggtgggacgcaggctcgttggccacagaccacatca 
GUSB   271 ggtgtgagcgatcaccatcttcaagtagtagccagcagattctaggtgggacgcaggctcgttggccacagaccacatca 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5330 cgaccgcggggtggttcttgtccctacgcaccacttcttccatcacctgcatgtggtgatgcagagaaacgttgttgaag 
Lab2  641 cgaccgcggggtggttcttgtccctacgcaccacttcttccatcacctgcatgtggtgatgcagagaaacgttgttgaag 
GUSB   191 cgaccgcggggtggttcttgtccctacgcaccacttcttccatcacctgcatgtggtgatgcagagaaacgttgttgaag 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5250 aactgcggcagcgccaggcccacgccgggacactcatcgatgaccacaatcccatagcggtcacacatctgcatcacttc 
Lab2  721 aactgcggcagcgccaggcccacgccgggacactcatcgatgaccacaatcccatagcggtcacacatctgcatcacttc 
GUSB  1 11 aactgcggcagcgccaggcccacgccgggacactcatcgatgaccacaatcccatagcggtcacacatctgcatcacttc 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5170 ctctgcataggggtagtggctggtacggaaaaagccgaattccagcacactggcggccgttactagtggatccgagctcg 
Lab2  801 ctctgcataggggtagtggctggtacggaaaaagccgaattccagcacactggcggccgttactagtggatccgagctcg 
GUSB    31 ctctgcataggggtagtggctggtacggaaa------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 5090 gtaccgagctcgaattcggcttgtccactcagccactggatttaagcagagttcaaatctgtactgcaccctggaggtgg 
Lab2  881 gtaccgagctcgaattcggcttgtccactcagccactggatttaagcagagttcaaatctgtactgcaccctggaggtgg 
GUSB       -------------------------------------------------------------------------------- 
BCR    1 ----------------------gtccactcagccactggatttaagcagagttcaaatctgtactgcaccctggaggtgg 
BCR-ABL      -------------------------------------------------------------------------------- 
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Lab1 5010 attcctttgggtattttgtgaataaagcaaagacgcgcgtctacagggacacagctgagccaaactggaacgaggaattt 
Lab2  961 attcctttgggtattttgtgaataaagcaaagacgcgcgtctacagggacacagctgagccaaactggaacgaggaattt 
GUSB       -------------------------------------------------------------------------------- 
BCR  59  attcctttgggtattttgtgaataaagcaaagacgcgcgtctacagggacacagctgagccaaactggaacgaggaattt 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4930 gagatagagctggagggctcccagaccctgaggatactgtgctatgaaaagtgttacaacaagacgaagatccccaagga 
Lab2 1041 gagatagagctggagggctcccagaccctgaggatactgtgctatgaaaagtgttacaacaagacgaagatccccaagga 
GUSB       -------------------------------------------------------------------------------- 
BCR  139 gagatagagctggagggctcccagaccctgaggatactgtgctatgaaaagtgttacaacaagacgaagatccccaagga 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4850 ggacggcgagagcacggacagactcatggggaagggccaggtccagctggacccgcaggccctgcaggacagagactggc 
Lab2 1121 ggacggcgagagcacggacagactcatggggaagggccaggtccagctggacccgcaggccctgcaggacagagactggc 
GUSB       -------------------------------------------------------------------------------- 
BCR  219 ggacggcgagagcacggacagactcatggggaagggccaggtccagctggacccgcaggccctgcaggacagagactggc 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4770 agcgcaccgtcatcgccatgaatgggatcgaagtaaagctctcggtcaagttcaacagcagggagttcagcttgaagagg 
Lab2 1201 agcgcaccgtcatcgccatgaatgggatcgaagtaaagctctcggtcaagttcaacagcagggagttcagcttgaagagg 
GUSB       -------------------------------------------------------------------------------- 
BCR  299 agcgcaccgtcatcgccatgaatgggatcgaagtaaagctctcggtcaagttcaacagcagggagttcagcttgaagagg 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4690 atgccgtcccgaaaacagacaggggtcttcggagtcaagattgctgtggtcaccaagagagagaggtccaaggtgcccta 
Lab2 1281 atgccgtcccgaaaacagacaggggtcttcggagtcaagattgctgtggtcaccaagagagagaggtccaaggtgcccta 
GUSB       -------------------------------------------------------------------------------- 
BCR  379 atgccgtcccgaaaacagacaggggtcttcggagtcaagattgctgtggtcaccaagagagagaggtccaaggtgcccta 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4610 catcgtgcgccagtgcgtggaggagatcgagcgccgaggcatggaggaggtgggcatctaccgcgtgtccggtgtggcca 
Lab2 1361 catcgtgcgccagtgcgtggaggagatcgagcgccgaggcatggaggaggtgggcatctaccgcgtgtccggtgtggcca 
GUSB       -------------------------------------------------------------------------------- 
BCR  459 catcgtgcgccagtgcgtggaggagatcgagcgccgaggcatggaggaggtgggcatctaccgcgtgtccggtgtggcca 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4530 cggacatccaggcactgaaggcagccttcgacgtcaataacaaggatgtgtcggtgatgatgagcgagatggacgtgaac 
Lab2 1441 cggacatccaggcactgaaggcagccttcgacgtcaataacaaggatgtgtcggtgatgatgagcgagatggacgtgaac 
GUSB       -------------------------------------------------------------------------------- 
BCR  539 cggacatccaggcactgaaggcagccttcgacgtcaataacaaggacgtgtcggtgatgatgagcgagatggacgtgaac 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4450 gccatcgcaggcacgctgaagctgtacttccgtgagctgcccgagcccctcttcactgacgagttctaccccaacttcgc 
Lab2 1521 gccatcgcaggcacgctgaagctgtacttccgtgagctgcccgagcccctcttcactgacgagttctaccccaacttcgc 
GUSB       -------------------------------------------------------------------------------- 
BCR  619 gccatcgcaggcacgctgaagctgtacttccgtgagctgcccgagcccctcttcactgacgagttctaccccaacttcgc 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4370 agagggcatcgctctttcagacccggttgcaaaggagagctgcatgctcaacctgctgctgtccctgccggaggccaacc 
Lab2 1601 agagggcatcgctctttcagacccggttgcaaaggagagctgcatgctcaacctgctgctgtccctgccggaggccaacc 
GUSB       -------------------------------------------------------------------------------- 
BCR  699 agagggcatcgctctttcagacccggttgcaaaggagagctgcatgctcaacctgctgctgtccctgccggaggccaacc 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4290 tgctcaccttccttttccttctggaccacctgaaaagggtggcagagaaggaggcagtcaataagatgtccctgcacaac 
Lab2 1681 tgctcaccttccttttccttctggaccacctgaaaagggtggcagagaaggaggcagtcaataagatgtccctgcacaac 
GUSB      -------------------------------------------------------------------------------- 
BCR  779 tgctcaccttccttttccttctggaccacctgaaaagggtggcagagaaggaggcagtcaataagatgtccctgcacaac 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4210 ctcgccacggtctttggccccacgctgctccggccctccgagaaggagagcaagctccctgccaaccccagccagcctat 
Lab2 1761 ctcgccacggtctttggccccacgctgctccggccctccgagaaggagagcaagctccctgccaaccccagccagcctat 
GUSB      -------------------------------------------------------------------------------- 
BCR  859 ctcgccacggtctttggccccacgctgctccggccctccgagaaggagagcaagctccctgccaaccccagccagcctat 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4130 caccatgactgacagctggtccttgaagccgaattcgtaatcatgtcatagctgtttcctgtgtgaaattgttatccgct 
Lab2 1841 caccatgactgacagctggtccttgaagccgaattcgtaatcatgtcatagctgtttcctgtgtgaaattgttatccgct 
GUSB      -------------------------------------------------------------------------------- 
BCR  939 caccatgactgacagctggtccttg------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 4050 cacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaa 
Lab2 1921 cacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaa 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
Lab1 3970 ttgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcgggg 
Lab2 2001 ttgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcgggg 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3890 agaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagc 
Lab2 2081 agaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3810 ggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaag 
Lab2 2161 ggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaag 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
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BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3730 gccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcac 
Lab2 2241 gccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcac 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3650 aaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccct 
Lab2 2321 aaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccct 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3570 cgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctc 
Lab2 2401 cgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3490 atagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcag 
Lab2 2481 atagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcag 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3410 cccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagc 
Lab2 2561 cccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3330 cactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctaca 
Lab2 2641 cactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctaca 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3250 ctagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggc 
Lab2 2721 ctagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3170 aaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaaga 
Lab2 2801 aaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaaga 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3090 tcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaa 
Lab2 2881 tcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaa 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 3010 aaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtct 
Lab2 2961 aaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtct 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
Lab1 2930 gacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccc 
Lab2 3041 gacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2850 cgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcac 
Lab2 3121 cgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcac 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2770 cggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctcc 
Lab2 3201 cggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctcc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2690 atccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgc 
Lab2 3281 atccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2610 tacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacat 
Lab2 3361 tacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacat 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2530 gatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgtta 
Lab2 3441 gatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgtta 
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GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2450 tcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagta 
Lab2 3521 tcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagta 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2370 ctcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgc 
Lab2 3601 ctcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2290 cacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttg 
Lab2 3681 cacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttg 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2210 agatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagc 
Lab2 3761 agatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2130 aaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttc 
Lab2 3841 aaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 2050 aatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaata 
Lab2 3921 aatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaata 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1970 ggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaacctataaaaa 
Lab2 4001 ggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaacctataaaaa 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
Lab1 1890 taggcgtatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggaga 
Lab2 4081 taggcgtatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggaga 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1810 cggtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcgg 
Lab2 4161 cggtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcgg 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1730 ggctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgt 
Lab2 4241 ggctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgt 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1650 aaggagaaaataccgcatcaggcgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctctt 
Lab2 4321 aaggagaaaataccgcatcaggcgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctctt 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1570 cgctattacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacga 
Lab2 4401 cgctattacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacga 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL      -------------------------------------------------------------------------------- 
 
Lab1 1490 cgttgtaaaacgacggccagtgccaagcttgcatgcctgcaggtcgactctctgcaccaagctcaagaagcagagcggag 
Lab2 4481 cgttgtaaaacgacggccagtgccaagcttgcatgcctgcaggtcgactctctgcaccaagctcaagaagcagagcggag 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL   1  ------------------------------------------------tctctgcaccaagctcaagaagcagagcggag 
 
Lab1 1410 gcaaaacgcagcagtatgactgcaaatggtacattccgctcacggatctcagcttccagatggtggatgaactggaggca 
Lab2 4561 gcaaaacgcagcagtatgactgcaaatggtacattccgctcacggatctcagcttccagatggtggatgaactggaggca 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL   33 gcaaaacgcagcagtatgactgcaaatggtacattccgctcacggatctcagcttccagatggtggatgaactggaggca 
 
Lab1 1330 gtgcccaacatccccctggtgcccgatgaggagctggacgctttgaagatcaagatctcccagatcaagagtgacatcca 
Lab2 4641 gtgcccaacatccccctggtgcccgatgaggagctggacgctttgaagatcaagatctcccagatcaagagtgacatcca 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  113 gtgcccaacatccccctggtgcccgatgaggagctggacgctttgaagatcaagatctcccagatcaagaatgacatcca 
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Lab1 1250 gagagagaagagggcgaacaagggcagcaaggctacggagaggctgaagaagaagctgtcggagcaggagtcactgctgc 
Lab2 4721 gagagagaagagggcgaacaagggcagcaaggctacggagaggctgaagaagaagctgtcggagcaggagtcactgctgc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  193 gagagagaagagggcgaacaagggcagcaaggctacggagaggctgaagaagaagctgtcggagcaggagtcactgctgc 
 
Lab1 1170 tgcttatgtctcccagcatggccttcagggtgcacagccgcaacggcaagagttacacgttcctgatctcctctgactat 
Lab2 4801 tgcttatgtctcccagcatggccttcagggtgcacagccgcaacggcaagagttacacgttcctgatctcctctgactat 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  273 tgcttatgtctcccagcatggccttcagggtgcacagccgcaacggcaagagttacacgttcctgatctcctctgactat 
 
Lab1 1090 gagcgtgcagagtggagggagaacatccgggagcagcagaagaagtgtttcagaagcttctccctgacatccgtggagct 
Lab2 4881 gagcgtgcagagtggagggagaacatccgggagcagcagaagaagtgtttcagaagcttctccctgacatccgtggagct 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  353 gagcgtgcagagtggagggagaacatccgggagcagcagaagaagtgtttcagaagcttctccctgacatccgtggagct 
 
Lab1 1010 gcagatgctgaccaactcgtgtgtgaaactccagactgtccacagcattccgctgaccatcaataaggaagatgatgagt 
Lab2 4961 gcagatgctgaccaactcgtgtgtgaaactccagactgtccacagcattccgctgaccatcaataaggaagatgatgagt 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  433 gcagatgctgaccaactcgtgtgtgaaactccagactgtccacagcattccgctgaccatcaataaggaagatgatgagt 
 
Lab1  930 ctccggggctctatgggtttctgaatgtcatcgtccactcagccactggatttaagcagagttcaaaagcccttcagcgg 
Lab2 5041 ctccggggctctatgggtttctgaatgtcatcgtccactcagccactggatttaagcagagttcaaaagcccttcagcgg 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  513 ctccggggctctatgggtttctgaatgtcatcgtccactcagccactggatttaagcagagttcaaaagcccttcagcgg 
Lab1  850 ccagtagcatctgactttgagcctcagggtctgagtgaagccgctcgttggaactccaaggaaaaccttctcgctggacc 
Lab2 5121 ccagtagcatctgactttgagcctcagggtctgagtgaagccgctcgttggaactccaaggaaaaccttctcgctggacc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  593 ccagtagcatctgactttgagcctcagggtctgagtgaagccgctcgttggaactccaaggaaaaccttctcgctggacc 
 
Lab1  770 cagtgaaaatgaccccaaccttttcgttgcactgtatgattttgtggccagtggagataacactctaagcataactaaag 
Lab2 5201 cagtgaaaatgaccccaaccttttcgttgcactgtatgattttgtggccagtggagataacactctaagcataactaaag 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  673 cagtgaaaatgaccccaaccttttcgttgcactgtatgattttgtggccagtggagataacactctaagcataactaaag 
 
Lab1  690 gtgaaaagctccgggtcttaggctataatcacaatggggaatggtgtgaagcccaaaccaaaaatggccaaggctgggtc 
Lab2 5281 gtgaaaagctccgggtcttaggctataatcacaatggggaatggtgtgaagcccaaaccaaaaatggccaaggctgggtc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  753 gtgaaaagctccgggtcttaggctataatcacaatggggaatggtgtgaagcccaaaccaaaaatggccaaggctgggtc 
 
Lab1  610 ccaagcaactacatcacgccagtcaacagtctggagaaacactcctggtaccatgggcctgtgtcccgcaatgccgctga 
Lab2 5361 ccaagcaactacatcacgccagtcaacagtctggagaaacactcctggtaccatgggcctgtgtcccgcaatgccgctga 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  833 ccaagcaactacatcacgccagtcaacagtctggagaaacactcctggtaccatgggcctgtgtcccgcaatgccgctga 
 
Lab1  530 gtatctgctgagcagcgggatcaatggcagcttcttggtgcgtgagagtgagagcagtcctggccagaggtccatctcgc 
Lab2 5441 gtatctgctgagcagcgggatcaatggcagcttcttggtgcgtgagagtgagagcagtcctggccagaggtccatctcgc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  913 gtatctgctgagcagcgggatcaatggcagcttcttggtgcgtgagagtgagagcagtcctggccagaggtccatctcgc 
 
Lab1  450 tgagatacgaagggagggtgtaccattacaggatcaacactgcttctgatggcaagctctacgtctcctccgagagccgc 
Lab2 5521 tgagatacgaagggagggtgtaccattacaggatcaacactgcttctgatggcaagctctacgtctcctccgagagccgc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL  993 tgagatacgaagggagggtgtaccattacaggatcaacactgcttctgatggcaagctctacgtctcctccgagagccgc 
 
Lab1  370 ttcaacaccctggccgagttggttcatcatcattcaacggtggccgacgggctcatcaccacgctccattatccagcccc 
Lab2 5601 ttcaacaccctggccgagttggttcatcatcattcaacggtggccgacgggctcatcaccacgctccattatccagcccc 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL 1073 ttcaacaccctggccgagttggttcatcatcattcaacggtggccgacgggctcatcaccacgctccattatccagcccc 
 
Lab1  290 aaagcgcaacaagcccactgtctatggtgtgtcccccaactacgacaagtgggagatggaacgcacggacatcaccatga 
Lab2 5681 aaagcgcaacaagcccactgtctatggtgtgtcccccaactacgacaagtgggagatggaacgcacggacatcaccatga 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL 1153 aaagcgcaacaagcccactgtctatggtgtgtcccccaactacgacaagtgggagatggaacgcacggacatcaccatga 
 
Lab1  210 agcacaagctgggcgggggccagtacggggaggtgtacgagggcgtgtggaagaaatacagcctgacggtggccgtgaag 
Lab2 5761 agcacaagctgggcgggggccagtacggggaggtgtacgagggcgtgtggaagaaatacagcctgacggtggccgtgaag 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL 1233 agcacaagctgggcgggggccagtacggggaggtgtacgagggcgtgtggaagaaatacagcctgacggtggccgtgaag 
 
Lab1  130 accttgaaggaggacaccatggaggtggaagagttcttgaaagaagctgcagtcatgaaagagatcaaacaccctaacct 
Lab2 5841 accttgaaggaggacaccatggaggtggaagagttcttgaaagaagctgcagtcatgaaagagatcaaacaccctaacct 
GUSB      -------------------------------------------------------------------------------- 
BCR      -------------------------------------------------------------------------------- 
BCR-ABL 1313 accttgaaggaggacaccatggaggtggaagagttcttgaaagaagctgcagtcatgaaagagatcaaacaccctaacct 
 
Lab1    50 ggtgcggtcgactctagatgcatgctcgagcggccgccagtgtgatggat     
Lab2  5921 ggtgcggtcgactctagatgcatgctcgagcggccgccagtgtgatggat 
GUSB       -------------------------------------------------- 
 BCR       --------------------------------------------------  
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BCR-ABL 1393  ggtgc--------------------------------------------- 
Two differences between the consensus sequences from Genbank and the sequences of the fragments 
present in pIRMM-0099 ware indicated in grey. 
 
48 
 
Annex G: Results of the Characterisation study for the copy number concentration of the 
plasmid 
Table G1: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623a 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 973463   
 2 884230   
1 3 1091851   
 4 1216974 12.66  
 5 1085891   
 6 1244606   
 7 990555   
 8 1076161 10.11  
2 9 1075208  n.c. 
 10 n.a.    
 11 1318816    
 12 1203224    
 13 850527    
 14 971317    
3 15 888295 16.88   
 16 1020358    
 17 1302875    
 18 1187144    
all measurements 1081264 13.03   
n.a.: not accepted, n.c.: cannot be calculated as MSbetween < MSwithin  
 
Table G2: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623b 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 89381   
 2 83629   
1 3 101269   
 4 120777 17.86  
 5 120027   
 6 131755   
 7 100105   
 8 108482 11.64  
2 9 107063  5.03 
 10 131156    
 11 130595    
 12 118884    
 13 84084    
 14 93263    
3 15 87540 14.17   
 16 99239    
 17 120806    
 18 110646    
all measurements 107706 15.12  
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Table G3: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623c 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 8619.9   
 2 10290.2   
1 3 11565.9   
 4 10984.8 9.46  
 5 10522.5   
 6 10582.7   
 7 9067.9   
 8 10612.3 12.95  
2 9 10842.0  6.25 
 10 13205.1    
 11 12194.6    
 12 10508.6    
 13 9232.2    
 14 8475.1    
3 15 9956.1 11.73   
 16 8255.1    
 17 9512.8    
 18 11344.6    
all measurements 10320.7 12.68  
 
 
Table G4: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623d 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 939.7   
 2 1033.0   
1 3 1113.7   
 4 1074.2 6.40  
 5 1100.1   
 6 984.1   
 7 869.1   
 8 1119.0 11.61  
2 9 1077.3  6.70 
 10 1244.1    
 11 1156.7    
 12 1039.1    
 13 893.2    
 14 838.2    
3 15 1028.9 10.15   
 16 818.2    
 17 960.8    
 18 1041.7    
all measurements 1018.4 11.20  
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Table G5: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623e 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 90.1   
 2 92.2   
1 3 104.6   
 4 120.4 11.40  
 5 114.1   
 6 99.9   
 7 94.3   
 8 110.0 11.43  
2 9 104.3  8.22 
 10 115.7    
 11 127.5    
 12 127.7    
 13 92.8    
 14 82.7    
3 15 88.3 8.72   
 16 95.5    
 17 95.8    
 18 107.9    
all measurements 103.5 12.81   
 
Table G6: Results of the characterisation study of the copy number concentration of the plasmid in ERM-
AD623f 
Laboratory 
number 
Measurement 
number Result swithin labs [%] sbetween labs [%] 
 1 n.a.   
 2 8.72   
1 3 9.60 15.43  
 4 12.63   
 5 9.66   
 6 8.61   
 7 8   
 8 11.75   
2 9 9.6 18.72 5.78 
 10 9.43    
 11 13.35    
 12 13.3    
 13 9.16    
 14 8.88    
3 15 7.78 6.68   
 16 9.66    
 17 10.54    
 18 8.72    
all measurements 9.96 15.96        
n.a.: not accepted  
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Annex H: Commutability study 
 
Table H1: qPCR methods used within the commutability study 
Laboratory 
number 
Control gene Reference of qPCR 
method qPCR instrument 
1 BCR [11] ABI 7000 (Applied Biosystems) 
2 ABL [5,6] ABI 7000 (Applied Biosystems) 
3 GUSB [5,6] ABI 7500 FAST (Applied Biosystems)
4 ABL [5,6] ABI 7900 HT (Applied Biosystems) 
ABL [5,6] 
5 GUSB [5,6] ABI 7900 HT (Applied Biosystems) 
ABL Home made 6 GUSB Home made LightCycler480 (Roche) 
ABL [26] 7 GUSB [23] LightCycler1.5 (Roche) 
8 BCR [11] ABI7500 (Applied Biosystems) 
ABL [5,6] 
BCR [11] 9 
GUSB [5,6] 
Rotorgene 6000 (Corbett) 
 
 
 
 
Figure H: Copy number ratios of BCR-ABL b3a2 to the three control genes: BCR, ABL and GUSB 
measured for two cDNA solutions by different expert laboratories using ERM-AD623 as calibrant. Blackpoint 
represents the mean of the ratio calculated for the two cDNA solutions. The bars represent an estimation of 
the measurement uncertainty based on a relative standard deviation of 30 % for qPCR measurements.  
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Abstract 
 
This certification report describes the processing and characterisation of ERM®-FA415v, a batch of Charpy 
V-notch certified reference test pieces certified for the absorbed energy (KV). Sets of five of these test 
pieces are used for the verification of pendulum impact test machines according to ISO 148-2 (Metallic 
materials - Charpy pendulum impact test – Part 2: Verification of testing machines [1]).  
The absorbed energy (KV) is procedurally defined and refers to the impact energy required to break a V-
notched test piece of standardised dimensions, as defined in ISO 148-1 [2]. The certified value of ERM®- 
FA415v is made traceable to the SI, via the SI-traceable certified value of the master batch ERM®-FA415b, 
by testing samples of ERM®- FA415v and ERM®-FA415b under repeatability conditions on an impact 
pendulum verified and calibrated with SI-traceably calibrated tools. The certified value is valid only for 
strikers with a 2 mm tip radius. The certified value is valid at (20 ± 2) °C. 
 
The certified value for KV (= energy required to break a V-notched test piece using a pendulum impact test 
machine) and the associated expanded uncertainties (k = 2 corresponding to a confidence level of about 
95 %) calculated for the mean of a set of five test pieces, are: 
 
Steel Charpy V-notch test pieces 
 
Certified value 2) 
[J] 
Uncertainty 3) 
[J]  
Absorbed energy (KV) 1) 156 7 
1) The absorbed energy (KV) is a method defined measurand. KV is the impact energy required to break a V-notched 
bar of standardised dimensions, as defined in ISO 148-1. The certified value is valid only for strikers with a 2 mm tip 
radius, and in the temperature range of (20 ± 2) °C. 
2) The certified value of ERM®-FA415v, and its uncertainty, is traceable to the International System of Units 
(SI), via the master batch ERM®-FA415b of the same nominal absorbed energy (150 J) by testing samples of 
ERM®-FA415b and ERM®-FA415v under repeatability conditions on an impact pendulum verified and calibrated 
with SI-traceable calibrated tools.  
3) Estimated expanded uncertainty of the mean KV of the 5 specimens (delivered as 1 set), with a coverage factor 
k = 2, corresponding to a level of confidence of about 95 %, as defined in ISO/IEC Guide 98-3, Guide to the 
expression of uncertainty in measurement (GUM:1995). The number of degrees of freedom of the certified 
uncertainty is RM = 53. 
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